Navigation Links
SXC Health Solutions announces contract with largest worker's compensation organization in the U.S.
Date:7/17/2009 

     - Company to provide industry-leading PBM technology solutions and
           services for the Ohio Bureau of Workers' Compensation -

LISLE, IL, July 17 /PRNewswire-FirstCall/ - SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC), a leading provider of technology and pharmacy benefit management (PBM) services, announces that its HealthCare Information Technology ("HCIT") Group has been awarded a contract to provide PBM solutions to the Ohio Bureau of Workers' Compensation. The contract period is for a three-year term with services commencing on November 1, 2009.

Under terms of the agreement, SXC will provide pharmacy claims adjudication, drug utilization review, pharmacy network management, clinical services to contain costs, Maximum Allowable Cost list management, and management reporting in support of more than an estimated 1.6 million workers' compensation cases annually. SXC will deliver services for injured workers within Ohio and nationally as necessary.

"We are very pleased to work with the Ohio Bureau of Workers' Compensation to ensure that high quality pharmacy services are provided to Ohio's injured workers, and that the Bureau is able to improve healthcare outcomes while reducing the costs of care," said Mark Thierer, President CEO of SXC Health Solutions. "The worker's compensation market has unique service characteristics that set up well for our technology-based PBM platform. We look forward to providing the Ohio Bureau of Workers' Compensation a strong PBM service offering."

About SXC Health Solutions Corp.

SXC Health Solutions Corp. is a leading provider of pharmacy benefit management (PBM) services and Healthcare Information Technology (HCIT) solutions to the healthcare benefits management industry. As the industry's "technology-enabled PBM"(
'/>"/>

SOURCE SXC Health Solutions Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Top Obama administration officials to hold rural health community forum
2. Compirion Healthcare Sponsors Webinar on 7 Mistakes That Lower Patient Satisfaction Scores
3. American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screenings and Discussion of HBO Series The Alzheimers Project
4. Spiritual Outlook Can Affect Mental Health in Breast Cancer
5. Pennsylvania Insurance Department Examinations to Focus on Health Insurance Competition
6. Congress Braces for Showdown Over Health-Care Reform
7. Center for Medicines & Healthy Aging(C) and BidRx(R) Partner to Help Consumers Save on Prescription Medications
8. American Society for Clinical Pathology Joins the National Healthcare Career Network
9. One Healthcare Solution and MedBeyond Partner to Provide Optimum Solution for EMR and Medical Billing
10. School of Health Management Honors 162 Graduating Students
11. Private and public insurance choices could help pay for national health care reform
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Exploring standards to advance microbial genomics 9201 1Exploring standards to advance microbial genomics 9201 2Exploring standards to advance microbial genomics 9201 3Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 1Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 2Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 3Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 1Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 2Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 3
Other Medicine Technology:Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 2Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 3Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 4Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 6Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 7Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 8Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8